Dr. Deborah Dunsire joins Neurvati Neurosciences

By: GWL Team | Wednesday, 17 April 2024

Dr. Deborah Dunsire joins as Neurvati Neurosciences’ new member and the new chair of the company's board of directors on April 15, 2024. It is a clinical-stage biotechnology company that is committed to addressing a broad range of neurological and psychiatric disorders.

In addition to Neurvati Neurosciences, Dr. Deborah is also the Board Member of Syros Pharmaceuticals from over 2 years now. Prior to joining this firm, she was employed with Ultragenyx for a decade and was the CEO of Lundbeck for half a decade. She has an extensive experience in the biotech and pharmaceuticals industry while having skills in Strategy development, portfolio prioritization and management, building effective cultures and retain talent.

M.D., president and chief executive officer of Neurvati, Bruce Leuchter said while expressing his excitement, “We are very excited to welcome Dr. Dunsire to the Neurvati board of directors. She is a renowned industry veteran with a proven track record of success in leading the development and management of neuroscience companies, most recently as CEO of H. Lundbeck A/S where she led the company through a period of significant growth.”

He added, “As we plan for several important milestones in both our clinical development programs and our business strategy, her insights and global reach within the neuroscience community will play a central role in helping us continue our progress and achieve new levels of momentum. We very much look forward to working with her."

Additionally, Dr. Deborah stated, “I am delighted to be joining the Neurvati Neurosciences board of directors at such an exciting time for the company with many pivotal business development and clinical milestones pending. The company has the team and resources in place to continue their growth trajectory and achieve rapid progress in multiple efforts to make a meaningful difference for people living with a broad range of neurological and psychiatric diseases and conditions. I look forward to bringing my experience and perspective to support these important efforts.”